- Home
- PCRX vs EYPT Comparison
PCRX vs EYPT Comparison
Compare PCRX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- EYPT
- Stock Information
- Founded
- PCRX 2006
- EYPT 1987
- Country
- PCRX United States
- EYPT United States
- Employees
- PCRX N/A
- EYPT N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- PCRX Health Care
- EYPT Industrials
- Exchange
- PCRX Nasdaq
- EYPT Nasdaq
- Market Cap
- PCRX 1.2B
- EYPT 579.4M
- IPO Year
- PCRX 2011
- EYPT 2005
- Fundamental
- Price
- PCRX $24.02
- EYPT $9.48
- Analyst Decision
- PCRX Buy
- EYPT Strong Buy
- Analyst Count
- PCRX 9
- EYPT 8
- Target Price
- PCRX $29.89
- EYPT $24.75
- AVG Volume (30 Days)
- PCRX 526.9K
- EYPT 821.1K
- Earning Date
- PCRX 07-29-2025
- EYPT 08-06-2025
- Dividend Yield
- PCRX N/A
- EYPT N/A
- EPS Growth
- PCRX N/A
- EYPT N/A
- EPS
- PCRX N/A
- EYPT N/A
- Revenue
- PCRX $702,772,000.00
- EYPT $56,042,000.00
- Revenue This Year
- PCRX $7.54
- EYPT N/A
- Revenue Next Year
- PCRX $10.78
- EYPT N/A
- P/E Ratio
- PCRX N/A
- EYPT N/A
- Revenue Growth
- PCRX 3.08
- EYPT 12.04
- 52 Week Low
- PCRX $11.16
- EYPT $3.91
- 52 Week High
- PCRX $29.33
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- PCRX 36.83
- EYPT 72.76
- Support Level
- PCRX $23.85
- EYPT $7.94
- Resistance Level
- PCRX $25.16
- EYPT $10.77
- Average True Range (ATR)
- PCRX 0.79
- EYPT 0.74
- MACD
- PCRX -0.12
- EYPT 0.10
- Stochastic Oscillator
- PCRX 8.20
- EYPT 85.87
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.